Related Experiment Video

Updated: May 25, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Targeting regulatory T cells

Christine Ménétrier-Caux1, Tyler Curiel, Julien Faget

  • 1Université de Lyon, F-69000, Lyon, France. christine.caux@lyon.unicancer.fr

Targeted Oncology
|February 14, 2012
PubMed

Insights

T regulatory cells (Treg) create an immunosuppressive tumor environment, hindering anti-cancer immunity. Inhibiting Treg function shows promise for improving cancer immunotherapy efficacy in both animal models and human treatments.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Cancers express tumor antigens, yet spontaneous immune rejection is rare, indicating a need to understand immune evasion mechanisms.
  • CD4(+)CD25(high) T regulatory cells (Treg) are key mediators of immune suppression in established cancers.
  • The tumor microenvironment often fosters an immunosuppressive milieu, limiting effective host antitumor responses.

Purpose of the Study:

  • To review Treg subpopulations and their suppressive mechanisms in cancer.
  • To explore the potential of Treg inhibition for enhancing antitumor immunity.
  • To discuss strategies for developing Treg-targeting cancer immunotherapies.

Main Methods:

  • Literature review of Treg biology and function in cancer.
  • Analysis of studies involving Treg depletion in preclinical cancer models.
  • Examination of current and proposed immunotherapeutic strategies targeting Tregs.

Main Results:

  • Treg depletion enhances endogenous antitumor immunity in animal cancer models.
  • Inhibition of Treg function improves the efficacy of active immunotherapy in preclinical settings.
  • Evidence suggests Treg targeting could overcome limitations in human cancer immunotherapy.

Conclusions:

  • Tregs are critical suppressors of antitumor immunity in cancer.
  • Targeting Treg function represents a promising strategy to enhance cancer immunotherapy.
  • Further research into Treg-specific immunotherapies is warranted for clinical application.

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.